

**FORMATO
EUROPEO PER IL
CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome e Cognome

Mauro Maniscalco

Data di nascita

15/10/1967

Telefono cellulare

Indirizzo posta elettronica

mauro.maniscalco@icsmaugeri.it mauro.maniscalco@unina.it
mauromaniscalco@hotmail.com

Incarico attuale

Professore Associato di Malattie Respiratorie (6D1- MED/10) presso Università degli Studi di Napoli “Federico II”
Responsabile U.O.C Riabilitazione Respiratoria presso ICS Maugeri IRCCS – Telese Terme (BN)
Direttore del Laboratorio di ricerca sullo ***Studio dei Markers Biologici di Infiammazione nell’Esalato*** ICS Maugeri IRCCS Telese Terme (BN)

**ISTRUZIONE
E FORMAZIONE**

1991

Università Federico II di Napoli.

Laurea in Medicina e Chirurgia con voti 110/110 e lode

1996

Università Federico II di Napoli

Specializzazione in Malattie dell’Apparato Respiratorio con voti 70/70 e lode

2003

Università Federico II di Napoli

Specializzazione in Medicina del Lavoro con voti 70/70 e lode

2006

Karolinska Institute di Stoccolma (Svezia).

Ph. D. in Fisiologia e Farmacologia

2018

Abilitazione Scientifica Nazionale per professore di I fascia 6-D1 (MED-10) (professore ordinario)

STAGE ALL’ESTERO

1994-1995

Dipartimento di Fisiopatologia Respiratoria Addenbrooke’s Hospital di Cambridge (UK). ***Fellow - Research***

Nov-Dic 1996

Dipartimento di Farmacologia e Medicina Respiratoria Università di Sheffield (UK). ***Fellow - Research***

Giu – Sett 2003

Dipartimento di Fisiologia e Farmacologia Karolinska Institute di Stoccolma (Svezia). ***Visiting - Research***

2008-2009

Dipartimento di Fisiologia e Farmacologia Karolinska Institute di Stoccolma (Svezia). ***Fellow - Research***

ESPERIENZA PROFESSIONALE

<i>Aprile 2022</i>	Dipartimento di Medicina Clinica e Chirurgia-Università Federico II <i>Professore Associato</i>
<i>Febbraio 2017- ad oggi</i>	IRCSS Istituti Clinici Scientifici Maugeri SPA <i>Responsabile U.O.C. Riabilitazione Respiratoria</i>
<i>Giugno 2016 - ad oggi</i>	IRCSS Istituti Clinici Scientifici Maugeri SPA <i>Responsabile del Laboratorio di ricerca sullo “Studio dei Markers Biologici di Infiammazione nell’Esalato”</i>
2003 - 2017	Ospedale Classificato Maria SS. Della Pietà Casoria (Na) <i>Dirigente medico U.O. Pneumologia</i>
Gen - Dic 2008	Università Federico II. U.O.C di Malattie Respiratorie <i>Contratto di collaborazione per progetto di ricerca</i>
1997-2003	Ministero della Difesa. Esercito Italiano <i>Dirigente Medico dei Servizi Sanitari (Capitano Medico)</i>
1998 – 1999	Servizi Sanitari della Provincia Autonoma di Trento <i>Specialistica Ambulatoriale in Pneumologia</i>

MADRELINGUA

Italiano

ALTRE LINGUE

INGLESE

ECCELLENTE

ECCELLENTE

ECCELLENTE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

ALTRO

STEERING COMMITTEE O PRINCIPAL INVESTIGATOR IN STUDI INTERNAZIONALI APPROVATI CON FINANZIAMENTO

- Vincitore di bando per Studio collaborativo finanziato **GSK global** su asma grave, Mepolizumab e Biomarcatori (**Proponente**).
- Vincitore di bando per Studio spontaneo finanziato **Astra-Zeneca Italia** su Benralizumab e biomarcatori polmonari. (**Proponente**).
- Vincitore di Bando competitivo delle Regione Campania sulle Malattie rare **SORGERE**: Studio sulle Obesità ipotalamiche Rare Genetiche e acquisite: Ricerca e prospettive (**Investigator**).
- Progetto Regionale di Farmacovigilanza attiva finanziato con i fondi FV 2012-2013-2014 Progetto dal titolo “Reazioni avverse ai farmaci utilizzati nella pratica clinica nel trattamento dei pazienti con Broncopneumopatia Cronica Ostruttiva” (**Investigator**).

- Bando competitivo Ministero dello Sviluppo Economico (MISE): **Progetto SAALUS: Smart Ambient Assisted Living Ubiquitous System** bando MISE DM 5/3/18 Capo II (**Investigator**).
- **Studio AIFA: ICSLIFE** Comparison of 1-year treatment with inhaled bronchodilators (LABD) plus inhaled glucocorticosteroids (ICS) versus LABD without ICS on re-hospitalizations and/or death in elderly patients with chronic obstructive pulmonary disease (COPD) recently hospitalized because of an acute exacerbation of COPD (**Principal Investigator**).
- **Trial clinico: Studio MATINEE** “Studio multicentrico, randomizzato, in doppio cieco, a gruppi paralleli, controllato con placebo su Mepolizumab 100 mg s.c. come trattamento aggiuntivo in partecipanti con BPCO che manifestano esacerbazioni frequenti e caratterizzati da livelli di eosinofili (EudraCT number 2018-001540-56)” (**Coordinatore Nazionale e Principal Investigator**)
- **Trial clinico: Studio TITANIA** di fase III, multicentrico, randomizzato, in doppio cieco, a dosaggio cronico, a gruppi paralleli, controllato verso placebo per valutare l’efficacia e la sicurezza di due posologie di Tozorakimab in partecipanti affetti da malattia polmonare ostruttiva cronica (BPCO) sintomatica con anamnesi di riacutizzazioni della BPCO. (EudraCT Number: 2022-501063-41-00) (**Principal Investigator**).
- **Trial clinico: Studio PROSPERO** di fase III, multicentrico, randomizzato, in doppio cieco, a dosaggio cronico, a gruppi paralleli, controllato verso placebo per valutare l’efficacia e la sicurezza di due posologie di Tozorakimab in partecipanti affetti da malattia polmonare ostruttiva cronica (BPCO) sintomatica con anamnesi di riacutizzazioni della BPCO. (EudraCT Number:: 2022-501063-41-00) (**Principal Investigator**).
- **Trial clinico: Studio INSMED** di fase IIB 1007-201 “A randomized Double Blind placebo controlled multicentre study to assess the efficacy safety and pharmacokinetics of INS 1007 Administered Once daily for 24 weeks in Subjects with non-cystic fibrosis bronchiectasis (**Principal Investigator**).
- **Trial clinico: Studio ARCADIA** “Assessing the Relationship between Cardiovascular and small Airway Disease and Acute events” (**Principal Investigator**).
- **Trial clinico: Studio PRIME.** Osservazionale, Prospettico, Multicentrico, Internazionale su modelli di Cura Di Pazienti Asmatici Lievi” (**Principal Investigator**).
- **Trial clinico: Studio MACC.** Tipologia ed eziologia dell’anemia nello scompenso cardiaco e nella BPCO (**Principal Investigator**).

PREMI DI RICERCA

2023 FELLOW DELL’ SOCIETÀ EUROPEA DI MALATTIE RESPIRATORIE (FERS)

2017 1° PREMIO INAIL – CONFINDUSTRIA PER LA SICUREZZA SUL LAVORO PER L’AZIENDA OERLIKON SPA

2005 PH. D. POSITION AL KAROLINSKA INSTITUTE DI
STOCCOLMA

2003 GRANT COME SHORT-TERM FELLOW-SHIP DELLA
SOCIETÀ EUROPEA DI MALATTIE RESPIRATORIE (ERS)

2003 GRANT DELLA HEART AND LUNG FOUNDATION DI
STOCCOMA (SVEZIA)

2002 BORSA DI STUDIO “PROGETTO SCAMBI
INTERNAZIONALI” DELL’UNIVERSITÀ FEDERICO II DI
NAPOLI

1996 PREMIATO PER IL LAVORO “MODULAZIONE DELLA
PRODUZIONE DI OSSIDO NITRICO NELL’UOMO A DIFFERENTI
LIVELLI DEL TRATTO RESPIRATORIO” FACOLTÀ DI
FARMACIA UNIVERSITÀ “FEDERICO II” DI NAPOLI.

ATTIVITÀ EDITORIALE DI REVISIONE

- Associate Editor: **Frontiers in Pharmacology**
- Associate Editor: **Exploration of Asthma & Allergy**
- Associate Editor: **Rassegna di Patologia dell’Apparato Respiratorio**
- Deputy Editor: **Monaldi Archives for Chest Diseases**
- Section Editor: **Multidisciplinary Respiratory Medicine**
- Editorial board: **Cells** IF 6.6
- Editorial board: **Respiratory Medicine** IF 4.1
- Editorial board: **Current Medicinal Chemistry** IF 4.3
- Editorial board: **Biomarkers in Medicine** IF 2.4
- Guest Editor: **Biomedicines** IF 6.1

Referee: Medical Research Council (UK), National Medical Research Council of Singapore, CNR and ZonMw, The Netherlands Organization for Health Research and Development.

Referee: Lancet respiratory Medicine, AJCCM, CHEST, Thorax, ERJ, ERJ open, European Journal Clinical Investigation, Journal of Applied Physiology, Respiration, Journal of Breath Research, Respiratory Medicine, Clinical Experimental Allergy. Occupational Medicine. Journal Thoracic diseases, BMC, PLOS One, American Journal of Rhinology, Multidisciplinary Respiratory Medicine, Allergy, Environmental Health, BMC pulmonary medicine. European Journal Internal Medicine, Biomedicines, Postgraduate Medicine .

BREVETTI

Contributo allo sviluppo ed impiego del **Brevetto N° US7270638** "Method and device for diagnosis using an oscillating airflow" e Brevetto Europeo EP1469775

ATTIVITÀ DI DOCENZA

- Docente al corso di Laurea in Medicina per studenti IV anno II semestre dall’anno accademico 2022.
- Docente al corso di laurea triennale per Tecnici di Radiologia II anno I semestre dall’anno accademico 2023.
- Docente al corso di laurea triennale per Fisioterapisti II anno I semestre dall’anno accademico 2023.
- Docente della Scuola di Specializzazione in Malattie dell’Apparato Respiratorio dell’Università “Federico II” di Napoli dal 2018.
- Docente della Scuola di Specializzazione in Medicina del Lavoro dell’Università “Federico II” di Napoli dal 2024.

- Docente della Scuola di Specializzazione in Cardiologia dell'Università "Federico II" di Napoli dal 2018.
- Decente del Master di II livello in Malattie Rare Polmonari Università Federico II di Napoli dall'anno 2023 a tutt'ora .
- Docente del Master di II Livello sulla Fragilità Università di Pavia anno 2024 - 25
- Docente a Contratto di Malattie dell'Apparato Respiratorio presso il corso di Laurea in Dietistica dell'Università del Molise dal Gennaio 2017 al 2019
- Docente di Fisiologia e Medicina Iperbarica nei corsi di formazione professionale presso l'Istituto per lo Sviluppo, la Formazione e la Ricerca nel Mediterraneo "ISFORM", autorizzati con delibera n° 5753/00 della Regione Campania. Dal 2002- al 2006
- Relatore al "Corso per l'Educazione Continua in Medicina" dell'Università "Federico II" di Napoli.
- Attività seminariale di farmacologia a studenti in medicina presso il Karolinska Institute di Stoccolma.
- Docente al corso post-universitario su rinite allergica e patologie associate Ospedali riuniti di Ancona (2012- 2013)

PARTECIPAZIONE ATTIVA A SOCIETÀ SCIENTIFICHE E TASK FORCE

- Dal 2023 Responsabile della Task Force di Ateneo PATH 2 sull' infiammazione allergica T2 dell'Università degli Studi di Napoli "Federico II"
- Dal 2021 Responsabile nazionale Gruppo di Studio di Fisiopatologia Respiratoria ed Esercizio AIPO.
- 2018-20 Coordinatore nazionale AIPO Sud Italia – Gruppo di studio riabilitazione.
- Dal 2018 Membro del Consiglio direttivo AIPO regione Campania e Basilicata
- Membro dell'ASSEMBLY 5.2 European Respiratory Society (ERS).

PUBBLICAZIONI SCIENTIFICHE (SCOPUS H-INDEX 37)

RICERCA ORIGINALE SU RIVISTE INTERNAZIONALI PEER REVIEWED

1. ENDOTHELIAL DYSFUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN UPDATE ON MECHANISMS, ASSESSMENT TOOLS AND TREATMENT STRATEGIES. MARCUCCIO G, CANDIA C, **MANISCALCO M**, AMBROSINO P. FRONT MED (LAUSANNE). 2025 FEB 12;12:1550716.
2. THE POTENTIAL ROLE OF NASAL CYTOLOGY IN RESPIRATORY DISEASES: CLINICAL RESEARCH AND FUTURE PERSPECTIVES. MARCUCCIO G, RAFFIO G, AMBROSINO P, CANDIA C, CANTONE E, DETORAKI A, **MANISCALCO M**; PATH2 TASK-FORCE. J CLIN MED. 2025 JAN 29;14(3):884.
3. PRE-BIOLOGIC FENO MIGHT PREDICT ANTI-IL-5/IL-5RA RESPONSE TO TREATMENT IN SEVERE ASTHMATICS. SPOSATO B, SCALESE M, CAMICIOTTOLI G, CARPAGNANO GE, PELAIA C, SANTUS P, PELAIA G, CAMELI P, BARGAGLI E, LACERENZA LG, RADOVANOVIC D, ROGLIANI P, **MANISCALCO M**, MASIERI S, CAVALIERE C, CORSICO AG, SCICHILONE N, BAGLIONI S, PERRELLA A, PAGGIARO P, RICCI A. J ASTHMA. 2025 JAN 17:1-6.
4. ADDRESSING OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN CHRONIC RESPIRATORY DISEASES: THE ROLE OF EXERCISE AND MULTIDISCIPLINARY REHABILITATION. AMBROSINO P, NOLANO M, CANDIA C, GRASSI G, **MANISCALCO M**. ANTIOXIDANTS (BASEL). 2024 DEC 17;13(12):1543.
5. PSYCHIATRIC DISORDERS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: CLINICAL SIGNIFICANCE AND TREATMENT STRATEGIES. MORETTA P, CAVALLO ND, CANDIA C, LANZILLO A, MARCUCCIO G, SANTANGELO G, MARCUCCIO L, AMBROSINO P, **MANISCALCO M**. J CLIN MED. 2024 OCT 26;13(21):6418. DOI: 10.3390/JCM13216418.
6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE'S EOSINOPHILIC PHENOTYPE: CLINICAL CHARACTERISTICS, BIOMARKERS AND BIOTHERAPY. **MANISCALCO M**, CANDIA C, AMBROSINO P, IOVINE A, FUSCHILLO S. EUR J INTERN MED. 2025 JAN;131:27-35. DOI: 10.1016/J.EJIM.2024.10.015.

7. A COMPARISON OF GOLD AND STAR SEVERITY STAGES IN INDIVIDUALS WITH COPD UNDERGOING PULMONARY REHABILITATION. AMBROSINO P, VITACCA M, MARCUCCIO G, SPANEVELLO A, AMBROSINO N, **MANISCALCO M**.CHEST. 2025 FEB;167(2):387-401. DOI: 10.1016/J.CHEST.2024.10.013.
8. EXPLORING THE IMPACT OF INHALED CORTICOSTEROIDS ON ENDOTHELIAL FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS UNDERGOING PULMONARY REHABILITATION.AMBROSINO P, CANDIA C, MEROLA C, LOMBARDI C, MANCUSI C, MATERA MG, CAZZOLA M, **MANISCALCO M**.J CLIN MED. 2024 SEP 27;13(19):5749.
9. REVEALING THE GAP: FRACTIONAL EXHALED NITRIC OXIDE AND CLINICAL RESPONSIVENESS TO BIOLOGICAL THERAPY IN SEVERE ASTHMA - A RETROSPECTIVE STUDY.**MANISCALCO M**, CANDIA C, VISCA D, D'AMATO M, CALABRESE C, AMBROSINO P, MOLINO A, FUSCHILLO S.ERJ OPEN RES. 2024 SEP 23;10(5):00296-2024.
10. REDUCING THE RISK OF DEATH - A POSSIBLE OUTCOME IN COPD PATIENTS. **MANISCALCO M**, CALZETTA L, ROGLIANI P, CAZZOLA M. EXPERT REV CLIN PHARMACOL. 2024 SEP 26:1-9.
11. EXHALED BREATH CONDENSATE (EBC) IN RESPIRATORY DISEASES: RECENT ADVANCES AND FUTURE PERSPECTIVES IN THE AGE OF OMIC SCIENCES. **MANISCALCO M**, CANDIA C, FUSCHILLO S, AMBROSINO P, PARIS D, MOTTA A.J BREATH RES. 2024 SEP 23;18(4).
12. LONG-TERM EFFECTS OF MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA: A 6-YEAR REAL-LIFE EXPERIENCE.STANZIOLA AA, CANDIA C, NAZZARO G, CASO A, MEROLA C, GALLOTTI L, **MANISCALCO M**. FRONT PHARMACOL. 2024 AUG 8;15:1449220.
13. INHALED CORTICOSTEROIDS IN SEVERE COPD PATIENTS WITH CARDIOVASCULAR DISEASES. AUTHORS' REPLY. PAPI A, FORINI G, **MANISCALCO M**, ALIANI M, FABBRI LM.EUR J INTERN MED. 2024 NOV;129:131-132.
14. ENDOTYPING CHRONIC RESPIRATORY DISEASES: T2 INFLAMMATION IN THE UNITED AIRWAYS MODEL. AMBROSINO P, MARCUCCIO G, RAFFIO G, FORMISANO R, CANDIA C, MANZO F, GUERRA C, LUBRANO E, MANCUSI C, **MANISCALCO M**.LIFE (BASEL). 2024 JUL 19;14(7):899. DOI: 10.3390/LIFE14070899.
15. IS THE REHABILITATION COMPLEXITY SCALE USEFUL IN INDIVIDUALS UNDERGOING IN-HOSPITAL PULMONARY REHABILITATION? REHABILITATION COMPLEXITY SCALE FOR RESPIRATORY PATIENTS - ITALIAN NETWORK.ARCH PHYS MED REHABIL. 2024;105(11):2150-2159.
16. A CLINICIAN'S GUIDE TO SINGLE VS MULTIPLE INHALER THERAPY FOR COPD. CAZZOLA M, ORA J, **MANISCALCO M**, ROGLIANI P. EXPERT REV RESPIR MED. 2024;18(7):457-468.
17. LONG-TERM INHALED CORTICOSTEROID TREATMENT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CARDIOVASCULAR DISEASE, AND A RECENT HOSPITALISED EXACERBATION: THE ICSLIFE PRAGMATIC, RANDOMISED CONTROLLED STUDY. PAPI A, FORINI G, **MANISCALCO M**, BARGAGLI E, CRIMI C, SANTUS P, MOLINO A, BANDIERA V, BARALDI F, D'ANNA SE, CARONE M, MARVISI M, PELAIA C, SCIOSCIA C, PATELLA V, ALIANI M, FABBRI LM; ICSLIFE STUDY GROUP.EUR J INTERN MED. 2024 OCT;128:104-111.
18. AUTOIMMUNITY AGAINST NUCLEUS AMBIGUOUS IS PUTATIVELY POSSIBLE IN BOTH LONG-COVID-19 AND VACCINATED SUBJECTS: SCIENTIFIC EVIDENCE AND WORKING HYPOTHESIS.D'ANNA SE, VITALE AM, D'AMICO G, CARUSO BAVISOTTO C, AMBROSINO P, CAPPELLO F, **MANISCALCO M**, MARINO GAMMAZZA A.BIOLOGY (BASEL). 2024 MAY 21;13(6):359.
19. ARE BIOLOGICS EFFECTIVE ON LUNG HYPERINFLATION IN PATIENTS WITH RESISTANT ASTHMA? A REPLY. CAZZOLA M, **MANISCALCO M**.RESPIR MED. 2024 JUN;227:107653.
20. EXPLORING NOVEL PERSPECTIVES ON EOSINOPHILIC INFLAMMATION IN SEVERE ASTHMA. CANDIA C, AMBROSINO P, D'ANNA SE, MOTTA A, **MANISCALCO M**.BIOMARK MED. 2024;18(8):357-361.
21. THE BENEFICIAL IMPACT OF PULMONARY REHABILITATION IN IDIOPATHIC PULMONARY FIBROSIS: A REVIEW OF THE CURRENT LITERATURE. ZAMPARELLI SS, LOMBARDI C, CANDIA C, IOVINE PR, REA G, VITACCA M, AMBROSINO P, BOCCHINO M, **MANISCALCO M**.J CLIN MED. 2024 MAR 30;13(7):2026.
22. UPREGULATION OF NOTCH SIGNALING AND CELL-DIFFERENTIATION INHIBITORY TRANSCRIPTION FACTORS IN STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS.DI STEFANO A, GNEMMI I, ROSANI U, **MANISCALCO M**, D'ANNA SE, BRUN P, CARRIERO V, BERTOLINI F, BALBI B, RICCIARDOLO FLM.INT J MOL SCI. 2024 MAR 14;25(6):3287.
23. QUALITY OF LIFE AND WORK FUNCTIONALITY IN SEVERE ASTHMA PATIENTS: THE IMPACT OF BIOLOGICAL THERAPIES. LESO V, CANDIA C, PACELLA D, MOLINO A, NOCERA C, **MANISCALCO M**, IAVICOLI IJ.OCCUP MED TOXICOL. 2024 MAR 20;19(1):8.
24. IMPACT OF BIOLOGICS ON LUNG HYPERINFLATION IN PATIENTS WITH SEVERE ASTHMA. **MANISCALCO M**, CANDIA C, CALABRESE C, D'AMATO M, MATERA MG, MOLINO A, CAZZOLA M.RESPIR MED. 2024;225:107578.
25. EXPLORING THE ROLE OF NITRIC OXIDE IN LOWER AIRWAY DISEASES: INSIGHTS AND REAL-WORLD APPLICATION. AMBROSINO P, MARCUCCIO G, **MANISCALCO M**.CURR MED CHEM. 2024;31(37):6013-6017.
26. THE ROLE OF HIGH-FLOW NASAL CANNULA OXYGEN THERAPY IN EXERCISE TESTING AND PULMONARY REHABILITATION: A REVIEW OF THE CURRENT LITERATURE. CANDIA C, LOMBARDI C, MEROLA C, AMBROSINO P, D'ANNA SE, VICARIO A, DE MARCO S, MOLINO A, **MANISCALCO M**.J CLIN MED. 2023 30;13(1):232. THE BIOMARKERS' LANDSCAPE OF POST-COVID-19 PATIENTS CAN SUGGEST SELECTIVE CLINICAL INTERVENTIONS. PARIS D,

- PALOMBA L, ALBERTINI MC, TRAMICE A, MOTTA L, GIAMMATTEI E, AMBROSINO P, **MANISCALCO M**, MOTTA A. SCI REP. 2023 DEC 15;13(1):22496.
27. EXHALED NITRIC OXIDE AS BIOMARKER OF TYPE 2 DISEASES. **MANISCALCO M**, FUSCHILLO S, MORMILE I, DETORAKI A, SARNELLI G, PAULIS A, SPADARO G, CANTONE E; PATH-2 TASK FORCE. CELLS. 2023;12 (21):2518. DOI: 10.3390/CELLS12212518. PMID: 37947596
 28. CARDIOVASCULAR RISK ASSOCIATED WITH ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) GENOTYPES: A META-ANALYSIS WITH META-REGRESSIONS. AMBROSINO P, MARCUCCIO G, LOMBARDI C, D'ANNA SE, SANDUZZI ZAMPARELLI S, MANCUSI C, SPEDICATO GA, MOTTA A, **MANISCALCO M**. J CLIN MED. 2023;12(20):6490. DOI: 10.3390/JCM12206490. PMID: 37892629
 29. BONE MORPHOGENIC PROTEINS AND THEIR ANTAGONISTS IN THE LOWER AIRWAYS OF STABLE COPD PATIENTS. DI STEFANO A, ROSANI U, LEVRA S, GNEMMI I, BRUN P, **MANISCALCO M**, D'ANNA SE, CARRIERO V, BERTOLINI F, RICCIARDOLO FLM. BIOLOGY (BASEL). 2023;12(10):1304. DOI: 10.3390/BIOLOGY12101304. PMID: 37887014
 30. NASAL NITRIC OXIDE AND CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: IS IT A MATTER OF INFLAMMATION OR MECHANICAL OBSTRUCTION? AMBROSINO P, MOTTA A, **MANISCALCO M**. INT FORUM ALLERGY RHINOL. 2023. DOI: 10.1002/ALR.23291.
 31. BEYOND VISUAL INTERPRETATION: QUANTITATIVE ANALYSIS AND ARTIFICIAL INTELLIGENCE IN INTERSTITIAL LUNG DISEASE DIAGNOSIS "EXPANDING HORIZONS IN RADIOLOGY". REA G, SVERZELLATI N, BOCCHINO M, LIETO R, MILANESE G, D'ALTO M, BOCCHINI G, **MANISCALCO M**, VALENTE T, SICA G. DIAGNOSTICS (BASEL). 2023;13(14):2333. DOI: 10.3390/DIAGNOSTICS13142333.
 32. THE CLINICAL APPLICATION OF ESTABLISHED AND EMERGING BIOMARKERS FOR CHRONIC RESPIRATORY DISEASES. AMBROSINO P, MARCUCCIO G, MANZO F, MANCUSI C, MEROLA C, **MANISCALCO M**. J CLIN MED. 2023;12(19):6125. DOI: 10.3390/JCM12196125. PMID: 37834769
 33. FLOW-MEDIATED DILATION AS A MARKER OF ENDOTHELIAL DYSFUNCTION IN PULMONARY DISEASES: A NARRATIVE REVIEW. ABAGNALE L, CANDIA C, MOTTA A, GALLOWAY B, AMBROSINO P, MOLINO A, **MANISCALCO M**. RESPIR MED RES. 2023; 84:101049. DOI: 10.1016/J.RESMER.2023.101049
 34. EFFECTS OF PULMONARY REHABILITATION IN SURVIVORS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2. ROLE OF VACCINATION. VIGNA M, CERIANA P, SANTOMASSIMO M, VITACCA M, **MANISCALCO M**, AMBROSINO N. MONALDI ARCH CHEST DIS. 2023. DOI: 10.4081/MONALDI.2023. 2738. PMID: 377323
 35. CLINICAL APPLICATIONS OF NASAL NITRIC OXIDE IN ALLERGIC RHINITIS: A REVIEW OF THE LITERATURE. MARCUCCIO G, AMBROSINO P, MEROLA C, MANZO F, MOTTA A, REA G, CANTONE E, **MANISCALCO M**. J CLIN MED. 2023;12(15):5081. DOI: 10.3390/JCM12155081. PMID: 37568482
 36. DETECTION OF CELLS IN EXHALED BREATH CONDENSATE HOLDS POTENTIAL FOR PATHOPHYSIOLOGICAL INSIGHTS IN PULMONARY DISEASES. PALOMBA L, PARIS D, TRAMICE A, AMBROSINO P, **MANISCALCO M**, MOTTA A. AM J RESPIR CELL MOL BIOL. 2023 JUL;69(1):113-115.
 37. EFFECT OF PULMONARY REHABILITATION ON COPD ASSESSMENT TEST ITEMS IN INDIVIDUALS CLASSIFIED AS GOLD GROUP. VITACCA M, PANERONI M, SPANEVELLO A, **MANISCALCO M**, DIASPARRA A, ALIANI M, AMBROSINO N. RESPIRATION. 2023; 102 (7):469-478. DOI: 10.1159/000531011.
 38. A MULTIDISCIPLINARY APPROACH FOR TYPE 2 ALLERGIC DISEASES: WHAT DO BIOLOGICS TEACH US? **MANISCALCO M**, DETORAKI A, SARNELLI G, NOLANO M, DE PAULIS A, SPADARO G, CANTONE E; PATH-2 TASK FORCE. J PERS MED. 2023 JUN 1;13(6):941. DOI: 10.3390/JPM13060941.
 39. PULMONARY REHABILITATION AND ENDOTHELIAL FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A PROSPECTIVE COHORT STUDY. AMBROSINO P, DI MINNO MND, D'ANNA SE, FORMISANO R, PAPPONE N, MANCUSI C, MOLINO A, MOTTA A, **MANISCALCO M**. EUR J INTERN MED. 2023 JUN 20; S0953-6205(23)00210-8. DOI: 10.1016/J.EJIM.2023.06.015.
 40. PHARMACOTHERAPIES IN OLDER ADULTS WITH COPD: CHALLENGES AND OPPORTUNITIES. MATERA MG, HANANIA NA, **MANISCALCO M**, CAZZOLA M. DRUGS AGING. 2023 JUL;40(7):605-619. DOI: 10.1007/S40266-023-01038-0.
 41. BACTERIAL LOAD AND RELATED INNATE IMMUNE RESPONSE IN THE BRONCHI OF RAPID DECLINERS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. D'ANNA SE, DOSSENA F, GNEMMI I, BRUN P, SPANEVELLO A, CARRIERO

V, BERTOLINI F, MANISCALCO M, RICCIARDOLO FL, BALBI B, DI STEFANO A. RESPIR MED. 2023 AUG-SEP; 215:107297. DOI: 10.1016/J.RMED.2023.107297.

42. CARDIAC AND PULMONARY REHABILITATION: TWO UNDERUTILIZED APPROACHES WITH SOME UNEXPECTED BENEFITS. AMBROSINO P, MARCUCCIO G, FORMISANO R, MARCUCCIO L, FILOSA R, MANISCALCO M. J CLIN MED. 2023 APR 13;12(8):2847. DOI: 10.3390/JCM12082847.
43. EOSINOPHILIC AIRWAY DISEASES: FROM PATHOPHYSIOLOGICAL MECHANISMS TO CLINICAL PRACTICE. MORMILE M, MORMILE I, FUSCHILLO S, ROSSI FW, LAMAGNA L, AMBROSINO P, DE PAULIS A, MANISCALCO M. INT J MOL SCI. 2023 APR 14;24(8):7254. DOI: 10.3390/IJMS24087254.
44. CLUSTERS OF INDIVIDUALS RECOVERING FROM AN EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND RESPONSE TO IN-HOSPITAL PULMONARY REHABILITATION. VITACCA M, MALOVINI A, SPANEVELLO A, CERIANA P, PANERONI M, MANISCALCO M, BALBI B, RIZZELLO L, MURGIA R, BELLAZZI R, AMBROSINO N. PULMONOLOGY. 2023 MAY-JUN;29(3):230-239. DOI: 10.1016/J.PULMOE.2023.01.002.
45. IMPLEMENTING TRANSLATIONAL RESEARCH TO UNDERSTAND THE FUTURE OF COVID-19 AND ITS LONG-TERM CONSEQUENCES: A DEGROWTH PERSPECTIVE OR THE TRANSFORMATION OF A GLOBAL EMERGENCY? AMBROSINO P, MORETTA P, LANZILLO A, FORMISANO R, MANISCALCO M. BIOMEDICINES. 2023 JAN 3;11(1):117. DOI: 10.3390/BIOMEDICINES11010117.
46. VALIDATION OF THE GLOBAL LUNG FUNCTION INITIATIVE 2012 SPIROMETRY REFERENCE VALUES IN A HEALTHY ITALIAN WORKING POPULATION. FONTANA L, CIOFFI DL, LESO V, D'AUSILIO E, PACELLA D, FEDELE M, MANISCALCO M, IAVICOLI I. INT J ENVIRON RES PUBLIC HEALTH. 2022 NOV 17; 19(22):15200.
47. FRACTIONAL EXHALED NITRIC OXIDE (FENO) IN PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: SHORT-TERM VARIABILITY AND POTENTIAL CLINICAL IMPLICATIONS. AMBROSINO P, FUSCHILLO S, ACCARDO M, MOSELLA M, MOLINO A, SPEDICATO GA, MOTTA A, MANISCALCO M. J PERS MED. 2022 NOV 16;12(11):1906.
48. CLINICAL ASSESSMENT OF ENDOTHELIAL FUNCTION IN CONVALESCENT COVID-19 PATIENTS: A META-ANALYSIS WITH META-REGRESSIONS. AMBROSINO P, SANDUZZI ZAMPARELLI S, MOSELLA M, FORMISANO R, MOLINO A, SPEDICATO GA, PAPA A, MOTTA A, DI MINNO MND, MANISCALCO M. ANN MED. 2022 DEC;54(1):3234-3249.
49. IS IT ALL ABOUT ENDOTHELIAL DYSFUNCTION? FOCUSING ON THE ALTERATION IN ENDOTHELIAL INTEGRITY AS A KEY DETERMINANT OF DIFFERENT PATHOLOGICAL MECHANISMS. AMBROSINO P, D'ANNA SE, GRASSI G, MANISCALCO M. BIOMEDICINES. 2022 OCT 31;10(11):2757. DOI: 10.3390/BIOMEDICINES10112757.
50. COGNITIVE IMPAIRMENT IN CONVALESCENT COVID-19 PATIENTS UNDERGOING MULTIDISCIPLINARY REHABILITATION: THE ASSOCIATION WITH THE CLINICAL AND FUNCTIONAL STATUS. MORETTA P, AMBROSINO P, LANZILLO A, MARCUCCIO L, FUSCHILLO S, PAPA A, SANTANGELO G, TROJANO L, MANISCALCO M. HEALTHCARE (BASEL). 2022 MAR 4;10(3):480. DOI: 10.3390/HEALTHCARE10030480.
51. A MACHINE LEARNING APPROACH TO PREDICT THE REHABILITATION OUTCOME IN CONVALESCENT COVID-19 PATIENTS. ADAMO S, AMBROSINO P, RICCIARDI C, ACCARDO M, MOSELLA M, CESARELLI M, D'ADDIO G, MANISCALCO M. J PERS MED. 2022 FEB 22;12(3):328. DOI: 10.3390/JPM12030328.
52. FUTURE PERSPECTIVES OF REEVALUATING MILD COPD. RADOVANOVIC D, CONTOLI M, BRAIDO F, MANISCALCO M, MICHELETTO C, SOLIDORO P, SANTUS P, CARONE M. RESPIRATION. 2022 APR 25;1-9. DOI: 10.1159/000524102. ONLINE AHEAD OF PRINT. PMID: 35468602
53. DECONDITIONING IN COVID-19 SURVIVORS WITH REDUCED EXERCISE PERFORMANCE: A ROLE FOR ENDOTHELIAL DYSFUNCTION? AMBROSINO P, MANISCALCO M. MED HYPOTHESES. 2022 JUN; 163:110847. DOI: 10.1016/J.MEHY.2022.110847.
54. PERIPHERAL NEUROPATHY IN PATIENTS RECOVERING FROM SEVERE COVID-19: A CASE SERIES. BALBI P, SALTALAMACCHIA A, LULLO F, FUSCHILLO S, AMBROSINO P, MORETTA P, LANZILLO B, MANISCALCO M. MEDICINA (KAUNAS). 2022 APR 8;58(4):523. DOI: 10.3390/MEDICINA58040523.
55. ENDOTHELIAL DYSFUNCTION IN COVID-19: A UNIFYING MECHANISM AND A POTENTIAL THERAPEUTIC TARGET. AMBROSINO P, CALCATERRA IL, MOSELLA M, FORMISANO R, D'ANNA SE, BACHETTI T, MARCUCCIO G, GALLOWAY B, MANCINI

FP, PAPA A, MOTTA A, DI MINNO MND, MANISCALCO M. BIOMEDICINES. 202230;10(4):812. DOI: 10.3390/BIOMEDICINES10040812. PMID: 35453563

56. A MACHINE LEARNING APPROACH TO PREDICT THE REHABILITATION OUTCOME IN CONVALESCENT COVID-19 PATIENTS. ADAMO S, AMBROSINO P, RICCIARDI C, ACCARDO M, MOSELLA M, CESARELLI M, D'ADDIO G, MANISCALCO M. J PERS MED. 2022 FEB 22;12(3):328. DOI: 10.3390/JPM12030328. PMID: 35330328
57. COGNITIVE IMPAIRMENT IN CONVALESCENT COVID-19 PATIENTS UNDERGOING MULTIDISCIPLINARY REHABILITATION: THE ASSOCIATION WITH THE CLINICAL AND FUNCTIONAL STATUS. MORETTA P, AMBROSINO P, LANZILLO A, MARCUCCIO L, FUSCHILLO S, PAPA A, SANTANGELO G, TROJANO L, MANISCALCO M. HEALTHCARE (BASEL). 2022 MAR 4;10 (3):480. DOI: 10.3390/HEALTHCARE10030480.
58. BRONCHODILATOR RESPONSE AS A POSSIBLE PREDICTOR OF LUNG FUNCTION IMPROVEMENT AFTER PULMONARY REHABILITATION IN POST-COVID-19 PATIENTS. MANISCALCO M, FUSCHILLO S, AMBROSINO P, D'ANNA SE, ACCARDO MS, MATERA MG, CAZZOLA M. ARCH BRONCONEUMOL. 2021 JUN 18:S0300-2896(21)00187-3. DOI: 10.1016/J.ARBRES.2021.06.004.
59. CARDIOPULMONARY EXERCISE PERFORMANCE AND ENDOTHELIAL FUNCTION IN CONVALESCENT COVID-19 PATIENTS. AMBROSINO P, PARRELLA P, FORMISANO R, PERROTTA G, D'ANNA SE, MOSELLA M, PAPA A, MANISCALCO M. J CLIN MED. 2022 MAR 7;11(5):1452. DOI: 10.3390/JCM11051452
60. METABOLOMICS OF COPD PULMONARY REHABILITATION OUTCOMES VIA EXHALED BREATH CONDENSATE. MANISCALCO M, PARIS D, CUOMO P, FUSCHILLO S, AMBROSINO P, TRAMICE A, PALOMBA L, MOTTA A. CELLS. 2022 JAN 20;11(3):344. DOI: 10.3390/CELLS11030344.
61. IDENTIFICATION OF BIOMARKERS IN COPD BY METABOLOMICS OF EXHALED BREATH CONDENSATE AND SERUM/PLASMA. PARIS D, PALOMBA L, TRAMICE A, MOTTA L, FUSCHILLO S, MANISCALCO M, MOTTA A. MINERVA MED. 2022 FEB 22. DOI: 10.23736/S0026-4806.22.07957-5.
62. PATHOGENESIS OF COPD AT THE CELLULAR AND MOLECULAR LEVEL. DI STEFANO A, GNEMMI I, DOSSENA F, RICCIARDOLO FL, MANISCALCO M, LO BELLO F, BALBI B. MINERVA MED. 2022 FEB 9. DOI: 10.23736/S0026-4806.22.07927-7.
63. CAN FENO BE A BIOMARKER IN THE POST-COVID-19 PATIENTS MONITORING? MANISCALCO M, AMBROSINO P, POTO R, FUSCHILLO S, POTO S, MATERA MG, CAZZOLA M. RESPIR MED. 2022 MAR;193:106745. DOI: 10.1016/J.RMED.2022.106745.
64. ENDOTHELIAL DYSFUNCTION: FROM A PATHOPHYSIOLOGICAL MECHANISM TO A POTENTIAL THERAPEUTIC TARGET. AMBROSINO P, GRASSI G, MANISCALCO M. BIOMEDICINES. 2021 DEC 31;10(1):78. DOI: 10.3390/BIOMEDICINES10010078.
65. COVID-19 AND POST-ACUTE COVID-19 SYNDROME: FROM PATHOPHYSIOLOGY TO NOVEL TRANSLATIONAL APPLICATIONS. AMBROSINO P, LANZILLO A, MANISCALCO M. BIOMEDICINES. 2021 DEC 27;10(1):47. DOI: 10.3390/BIOMEDICINES10010047.
66. THE RESPIRATORY REHABILITATION MAUGERI NETWORK SERVICE RECONFIGURATION AFTER 1 YEAR OF COVID-19. VITACCA M, CERIANA P, BALBI B, BRUSCHI C, ALIANI M, MANISCALCO M, FANFULLA F, DIASPARRA A, RIZZELLO L, SERENI D, SPANEVELLO A. MONALDI ARCH CHEST DIS. 2021 JUN 8;91(4). DOI: 10.4081/MONALDI.2021.1843.
67. COGNITIVE IMPAIRMENT AND ENDOTHELIAL DYSFUNCTION IN CONVALESCENT COVID-19 PATIENTS UNDERGOING REHABILITATION. MORETTA P, MANISCALCO M, PAPA A, LANZILLO A, TROJANO L, AMBROSINO P. EUR J CLIN INVEST. 2021 DEC 18:E13726. DOI: 10.1111/ECL.13726.
68. EFFECTIVENESS OF BENRALIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: DISTINCT SUB-PHENOTYPES OF RESPONSE IDENTIFIED BY CLUSTER ANALYSIS BY DI BONA ET AL. MANISCALCO M. CLIN EXP ALLERGY. 2021 NOV 18. DOI: 10.1111/CEA.14059.
69. PERFORMANCE OF FRACTIONAL EXHALED NITRIC OXIDE IN PREDICTING RESPONSE TO INHALED CORTICOSTEROIDS IN CHRONIC COUGH: A META-ANALYSIS. AMBROSINO P, ACCARDO M, MOSELLA M, PAPA A, FUSCHILLO S, SPEDICATO GA, MOTTA A, MANISCALCO M. ANN MED. 2021 DEC;53(1):1659-1672. DOI: 10.1080/07853890.2021.1979242.
70. A RAPID ANTIGEN DETECTION TEST TO DIAGNOSE SARS-COV-2 INFECTION USING EXHALED BREATH CONDENSATE BY A MODIFIED INFLAMMACHECK® DEVICE. MANISCALCO M, AMBROSINO P, CIULLO A, FUSCHILLO

S, VALENTE V, GAUDIOSI C, PARIS D, COBUCCIO R, STEFANELLI F, MOTTA A. SENSORS (BASEL). 2021;21(17):5710. DOI: 10.3390/S21175710.

71. DOES POOR GLYCEMIC CONTROL AFFECT THE IMMUNOGENICITY OF COVID-19 VACCINATION IN PATIENTS WITH TYPE 2 DIABETES: THE CAVEAT STUDY. MARFELLA R, D'ONOFRIO N, SARDU C, SCISCIOLA L, MAGGI P, COPPOLA N, ROMANO C, MESSINA V, TURRIZIANI F, SINISCALCO M, MANISCALCO M, BOCCALATTE M, NAPOLITANO G, SALEMME L, MARFELLA LV, BASILE E, MONTEMURRO MV, PAPA C, FRASCARIA F, PAPA A, RUSSO F, TIRINO V, PAPACCIO G, GALDIERO M, SASSO FC, BARBIERI M, RIZZO MR, BALESTRIERI ML, ANGELILLO IF, NAPOLI C, PAOLISSO G. DIABETES OBES METAB. 2021 DOI: 10.1111/DOM.14547.
72. MILD/MODERATE ASTHMA NETWORK IN ITALY (MANI): A LONG-TERM OBSERVATIONAL STUDY. BRAIDO F, BLASI F, CANONICA GW, PAGGIARO P, BEGHÈ B, BONINI M, CARPAGNANO GE, DEL GIACCO S, LAVORINI F, MILANESE M, PATELLA V, SANTUS P, CONTOLI M; MANI NETWORK, ALLEGRI C, BAIARDINI I, BONZANO L, CAIAFFA MF, CASTELNUOVO P, CORSICO AG, COSMI L, COSTANTINO MT, COTTINI M, CRIMI N, CRIVELLARO MA, D'ALÒ S, FOLLETTI I, FORNARI D, FOSCHINO-BARBARO MP, FRANCESCHINI L, GARGANO D, OLIANI KL, MANISCALCO M, MELISSARI L, MONTAGNI M, MONTUSCHI P, MURGIA N, PANNOFINO A, PAPI A, PARENTE R, PELAIA G, PINI L, PUGGIONI F, PULERÀ N, RESTA O, RICCIARDI L, RIDOLO E, SAVI E, SAVOIA F, SCALA G, SENNA G, TRIPODI S, VATRELLA A, VENTURA MT, VIVIANO VM, YACIOUB MR. J ASTHMA. 2021;1-6. DOI: 10.1080/02770903.2021.1968895.
73. PERSISTENT ENDOTHELIAL DYSFUNCTION IN POST-ACUTE COVID-19 SYNDROME: A CASE-CONTROL STUDY. AMBROSINO P, CALCATERRA I, MOLINO A, MORETTA P, LUPOLI R, SPEDICATO GA, PAPA A, MOTTA A, MANISCALCO M, DI MINNO MND. BIOMEDICINES. 2021 AUG 4;9(8):957. DOI: 10.3390/BIOMEDICINES9080957.
74. METABOLOMIC PROFILING OF EXHALED BREATH CONDENSATE AND PLASMA/SERUM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. FUSCHILLO S, PARIS D, TRAMICE A, AMBROSINO P, PALOMBA L, MANISCALCO M, MOTTA A. CURR MED CHEM. 2021 AUG 10. DOI: 10.2174/0929867328666210810122350.
75. BRONCHODILATOR RESPONSE AS A POSSIBLE PREDICTOR OF LUNG FUNCTION IMPROVEMENT AFTER PULMONARY REHABILITATION IN POST-COVID-19 PATIENTS. MANISCALCO M, FUSCHILLO S, AMBROSINO P, D'ANNA SE, ACCARDO MS, MATERA MG, CAZZOLA M. ARCH BRONCHOPULMONOL. 2021 JUN 18. DOI: 10.1016/J.ARBRES.2021.06.004.
76. CLINICAL ASSESSMENT OF ENDOTHELIAL FUNCTION IN CONVALESCENT COVID-19 PATIENTS UNDERGOING MULTIDISCIPLINARY PULMONARY REHABILITATION. AMBROSINO P, MOLINO A, CALCATERRA I, FORMISANO R, STUFANO S, SPEDICATO GA, MOTTA A, PAPA A, DI MINNO MND, MANISCALCO M. BIOMEDICINES. 2021 ;9(6):614. DOI: 10.3390/BIOMEDICINES9060614.
77. PULMONARY REHABILITATION IN PATIENTS WITH INTERSTITIAL LUNG DISEASES: CORRELATES OF SUCCESS. BRUNETTI G, MALOVINI A, MANISCALCO M, BALESTRINO A, CARONE M, VISCA D, CAPELLI A, VITACCA M, BELLAZZI R, PIAGGI G, FUSCHILLO S, ALIANI M, SPANEVELLO A, PRINCE I, PANERONI M, AMBROSINO N. RESPIR MED. 2021; 185:106473. DOI: 10.1016/J.RMED.2021.106473. EPUB 2021.
78. PREEXISTING CARDIORESPIRATORY COMORBIDITY DOES NOT PRECLUDE THE SUCCESS OF MULTIDISCIPLINARY REHABILITATION IN POST-COVID-19 PATIENTS. MANISCALCO M, FUSCHILLO S, AMBROSINO P, MARTUCCI M, PAPA A, MATERA MG, CAZZOLA M. RESPIR MED. 2021;184: 106470. DOI: 10.1016/J.RMED.2021.106470.
79. COVID-19 AND DIFFUSING CAPACITY OF THE LUNGS FOR CARBON MONOXIDE: A CLINICAL BIOMARKER IN POSTACUTE CARE SETTINGS. FUSCHILLO S, AMBROSINO P, MOTTA A, MANISCALCO M. BIOMARK MED. 2021 JUN;15(8):537-539. DOI: 10.2217/BMM-2021-0134. 33988464
80. DIAGNOSTIC ACCURACY OF D-DIMER TESTING FOR RECURRENT VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW WITH META-ANALYSIS.: VTE RECURRENCE AND D-DIMER. DI MINNO MND, CALCATERRA I, PAPA A, LUPOLI R, DI MINNO A, MANISCALCO M, AMBROSINO P. EUR J INTERN MED. 2021; 89:39-47. DOI: 10.1016/J.EJIM.2021.04.004.
81. MEPOLIZUMAB IMPROVES SINO-NASAL SYMPTOMS AND ASTHMA CONTROL IN SEVERE EOSINOPHILIC ASTHMA PATIENTS WITH CHRONIC RHINOSINUSITIS AND NASAL POLYPS: A 12-MONTH REAL-LIFE STUDY. DETORAKI A, TREMANTE E, D'AMATO M, CALABRESE C, CASELLA C, MANISCALCO M, POTO R, BRANCACCIO R, BOCCIA M, MARTINO M, IMPERATORE C, SPADARO G. THER ADV RESPIR DIS. 2021; 15:17534666211009398. DOI: 10.1177/17534666211009398.

82. BRONCHODILATOR REVERSIBILITY TESTING IN POST-COVID-19 PATIENTS UNDERGOING PULMONARY REHABILITATION.MANISCALCO M, AMBROSINO P, FUSCHILLO S, STUFANO S, SANDUZZI A, MATERA MG, CAZZOLA M. RESPIR MED. 2021; 182:106401. DOI: 10.1016/J.RMED.2021.106401.
83. CLINICAL ASSESSMENT OF ENDOTHELIAL FUNCTION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A META-ANALYSIS WITH META-REGRESSIONS.AMBROSINO P, PAPA A, BUONAURO A, MOSELLA M, CALCATERRA I, SPEDICATO GA,MANISCALCO M, DI MINNO MND. EUR J CLIN INVEST. 2021;51(8):E13552. DOI: 10.1111/ECL.13552. PMID: 33749828
84. RISK ASSESSMENT AND ANTITHROMBOTIC STRATEGIES IN ANTIPHOSPHOLIPID ANTIBODY CARRIERS.CALCATERRA I, AMBROSINO P, VITELLI N, LUPOLI R, ORSINI RC, CHIURAZZI M, MANISCALCO M, DI MINNO MND. BIOMEDICINES. 2021; 9(2):122. DOI: 10.3390/BIOMEDICINES9020122.
85. THE NITRIC OXIDE VIEW: PERSPECTIVES AND APPLICATIONS. MANISCALCO M. CURR MED CHEM. 2020; 27(42):7134-7135. DOI: 10.2174/092986732742201105102021.PMID: 33342396
86. NMR PROFILING OF EXHALED BREATH CONDENSATE DEFINES DIFFERENT METABOLIC PHENOTYPES OF NON-CYSTIC FIBROSIS BRONCHIECTASIS. PARIS D, PALOMBA L, MIRRA V, BORRELLI M, CORCIONE A, SANTAMARIA F, MANISCALCO M, MOTTA A. INT J MOL SCI. 2020;21(22):8600. DOI: 10.3390/IJMS21228600.
87. HEART RATE TURBULENCE IN OBSTRUCTIVE SLEEP APNEA SYNDROME: THE EFFECT OF SHORT-TERM CPAP THERAPY.D'ADDIO G, DE FELICE A, DONISI L, BRAGHIROLI A, MANISCALCO M. EUR J INTERN MED. 2021:111-114. DOI: 10.1016/J.EJIM.2020.12.015. PMID: 33390320
88. BASOPHIL ACTIVATION TEST FOR STAPHYLOCOCCUS AUREUS ENTEROTOXINS IN SEVERE ASTHMATIC PATIENTS. FLORA M, PERNA F, ABBADESSA S, GARZIANO F, MAFFUCCI R, MANISCALCO M, MOLLIKA M, PELAIA C, TREMANTE E, MAFFEI M, CALABRESE C. CLIN EXP ALLERGY. 2020. DOI: 10.1111/CEA.13772.
89. MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN BARTHEL INDEX DYSPNEA IN PATIENTS WITH COPD.VITACCA M, MALOVINI A, BALBI B, ALIANI M, CIRIO S, SPANEVELLO A, FRACCHIA C,MANISCALCO M, CORICA G, AMBROSINO N, PANERONI M.INT J CHRON OBSTRUCT PULMON DIS. 2020; 15:2591-2599
90. MEPOLIZUMAB EFFECTIVENESS AND ALLERGIC STATUS IN REAL LIFE.SPOSATO B, SCALESE M, CAMICIOTTOLI G, CARPAGNANO GE, PELAIA C, SANTUS P, MANISCALCO M, CORSICO A, GROSSO A, BAGLIONI S, MURGIA N, FOLLETTI I, PELAIA G, MASIERI S, CAVALIERE C, MUSARRA A, BARGAGLI E, RICCI A, LATORRE M, PAGGIARO P, ROGLIANI P. INT ARCH ALLERGY IMMUNOL. 2020 28:1-8
91. REAL-LIFE MEPOLIZUMAB EFFECTIVENESS IN SEVERE EOSINOPHILIC ASTHMATICS WITH NASAL POLYPOSIS. POSATO B, SCALESE M, CAMICIOTTOLI G, CARPAGNANO GE, PELAIA C, SANTUS P, MANISCALCO M, CORSICO A, GROSSO A, BAGLIONI S, MURGIA N, FOLLETTI I, PELAIA G, MASIERI S, CAVALIERE C, MUSARRA A, BARGAGLI E, RICCI A, LATORRE M, ROGLIANI P, PAGGIARO P. RESPIR MED RES. 2020; 78:100791
92. BACTERIAL AND VIRAL INFECTIONS AND RELATED INFLAMMATORY RESPONSES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. D'ANNA SE, MANISCALCO M, CAPPELLO F, CARONE M, MOTTA A, BALBI B, RICCIARDOLO FM, CARAMORI G, DI STEFANO A. ANN MED. 2020:1-39.
93. BLOOD BIOMARKERS INDICATE THAT THE PRECLINICAL STAGES OF ALZHEIMER'S DISEASE PRESENT OVERLAPPING MOLECULAR FEATURES.DI COSTANZO A, PARIS D, MELCK D, ANGIOLILLO A, CORSO G, MANISCALCO M, MOTTA A.SCI REP. 2020;10(1):15612
94. BIOMARKERS FOR IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL-CELL LUNG CANCER.FUSCHILLO S, BATILORO C, ROCCO D, D GRAVARA L, MOTTA A, MANISCALCO M. BIOMARK MED. 2020;14(11):929-932
95. COVID-19 AND FUNCTIONAL DISABILITY: CURRENT INSIGHTS AND REHABILITATION STRATEGIES. AMBROSINO P, PARRELLA P, FORMISANO R, PAPA A, MANISCALCO M, DI MINNO D. 2020 POSTGRADUATE J MEDICINE.
96. EXERGAMING AS AN ADDITIONAL TOOL FOR HOME-BASED REHABILITATION DURING COVID-19 PANDEMIC ERA. GAMES FOR HEALTH JOURNAL 2020
97. PORTABLE OXYGEN CONCENTRATOR V/S. OXYGEN CYLINDER IN CHRONIC LUNG DISEASE: PATIENT PREFERENCES AND PSYCHOLOGICAL IMPLICATIONS. P MORETTA, A MOLINO, M MARTUCCI, S FUSCHILLO, A DE FELICE, P GUIDA, A

98. A CASE SCENARIO STUDY FOR THE ASSESSMENT OF PHYSICIAN'S BEHAVIOR IN THE MANAGEMENT OF COPD: THE PROGETTO PADRE. MANISCALCO M, MARTUCCI M, FUSCHILLO S, DE FELICE A, D'ANNA S, CAZZOLA M. RESPIRATORY MEDICINE 2020
99. CLINICAL APPLICATION OF NASAL NITRIC OXIDE MEASUREMENT IN ALLERGIC RHINITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. AMBROSINO P, PARRELLA P, FORMISANO R, ODIERNA L, DI MINNO M, MOTTA A, MANISCALCO M. ANNALS OF ALLERGY AND IMMUNOLOGY. 2020
100. NITRIC OXIDE AND HYDROGEN SULFIDE: A NICE PAIR IN THE RESPIRATORY SYSTEM. FUSCHILLO S, PALOMBA L, CAPPARELLI R, MOTTA A, MANISCALCO M. CURRENT MEDICINAL CHEMISTRY. 2020
101. EVALUATION OF INNATE IMMUNE MEDIATORS RELATED TO RESPIRATORY VIRUSES IN THE LUNG OF STABLE COPD PATIENTS. D'ANNA S, MANISCALCO M, V CARRIERO, I GNEMMI, FL.M. RICCIARDOLO, G CARAMORI, L RIGHI, P BRUN, B BALBI, A DI STEFANO. JOURNAL OF CLINICAL MEDICINE 2020
102. NASAL NITRIC OXIDE AND NASAL POLYPOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. AMBROSINO P, MOLINO A., PARRELLA P, FORMISANO R, MOTTA A DI MINNO M, MANISCALCO M. JOURNAL CLINICAL MEDICINE 2020
103. PERIPHERAL BLOOD-BASED BIOMARKERS IN THE ALZHEIMER'S DISEASE CLINICAL SPECTRUM. DI COSTANZO A, PARIS D, MELCK D, ANGIOLILLO A, CORSO G, MANISCALCO M, MOTTA A. SCIENTIFIC REPORT 2020 IN PRESS
104. MEPOLIZUMAB EFFECTIVENESS ON SMALL AIRWAY OBSTRUCTION, CORTICOSTEROID SPARING AND MAINTENANCE THERAPY STEP-DOWN IN REAL LIFE. PULMONARY PHARMACOLOGY AND THERAPEUTICS. 2020
105. FRACTIONAL EXHALED NITRIC OXIDE (FENO) IN THE MANAGEMENT OF ASTHMA: A POSITION PAPER OF THE ITALIAN RESPIRATORY SOCIETY (SIP/IRS) AND ITALIAN SOCIETY OF ALLERGY, ASTHMA AND CLINICAL IMMUNOLOGY (SIAAIC). HEFFLER E, CARPAGNANO GE, FAVERO E, GUIDA G, MANISCALCO M, MOTTA A, PAOLETTI G, ROLLA G, BARALDI E, PEZZELLA V, PIACENTINI G, NARDINI S. MULTIDISCIP RESPIR MED 2020 FEB 19;15(1):36. DOI: 10.4081/MRM.2020.36. ECOLLECTION 2020 JAN 28.
106. EXHALED NITRIC OXIDE AS A CLINICAL BIOMARKER FOR THE CHOICE OF BIOLOGICS FOR THE TREATMENT OF SEVERE ASTHMA. FUSCHILLO S, HEFFLER E, MANISCALCO M. BIOMARKERS IN MEDICINE 2020
107. METABOLOMICS APPROACH APPLIED TO BREATH EXHALED CONDENSATE. A METHODOLOGICAL APPROACH. MANISCALCO M, PARIS D, MELCK D, FUSCHILLO S, MOTTA A. CURRENT MEDICAL CHEMISTRY 2020
108. IMPLEMENTATION OF A REAL-WORLD BASED ICF SET FOR THE REHABILITATION OF RESPIRATORY DISEASES: A PILOT STUDY. VITACCA M, GIARDINI A, CORICA G, CERIANA P, CARONE M, BALBI B, FRACCHIA C, MANISCALCO M, FANFULLA F, SARNO N, RACCANELLI R, TRAVERSONI S, SPANEVELLO A. MINERVA MED. 2020 JUN;111(3):239-244.
109. OXIDATIVE AND NITROSATIVE STRESS INVOLVEMENT IN THE PATHOGENESIS OF OBSTRUCTIVE LUNG DISEASES OF INCREASING SEVERITY. DI STEFANO A., MANISCALCO M, BALBI B, RICCIARDOLO FLM. CURRENT MEDICINAL CHEMISTRY 2020
110. EXERCISE CAPACITY AND COMORBIDITIES IN PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA. JOURNAL OF CLINICAL SLEEP MEDICINE 2020
111. ASSOCIATION BETWEEN EXHALED NITRIC OXIDE AND NASAL POLYPOSIS IN SEVERE ASTHMA. MANISCALCO M, CALABRESE C, MARIA D'AMATO M, GUIDA P, MOLINO A, ALIANI M, DE TULLIO F, FOSCHINO M, RICCIARDOLO F, CARPAGNANO G. RESPIR MED. 2019;152:20-24.
112. TRANSCUTANEOUS CARBON DIOXIDE MEASUREMENT IN THE ACUTE MEDICAL SETTING. MANISCALCO M, FUSCHILLO S. EUR RESP J 2019
113. BLOOD EOSINOPHILS AS BIOMARKERS OF RESPONSE TO THE THERAPY IN COPD. FUSCHILLO S, MOLINO A, STELLATO C. MOTTA A, MANISCALCO M. EUR J INTERN MED. 2019 JUL 12. PII: S0953-6205(19)30224-9.
114. BIOMARKERS IN CARDIAC REHABILITATION. ACANFORA D, FUSCHILLO S, MOTTA A MANISCALCO M. BIOMARK MED. 2019 JUN;13(9):701-705.
115. IS TWO BETTER THAN ONE? THE IMPACT OF DOUBLING TRAINING VOLUME IN SEVERE COPD: A RANDOMIZED CONTROLLED STUDY MARA PANERONI *,

IOANNIS VOGIATZIS, STEFANO BELLI, GLORIA SAVIO, DINA VISCA, ELISABETTA ZAMPOGNA, MARIA ALIANI, VITO DE CAROLIS, MAURO MANISCALCO, CARLA SIMONELLI, MICHELE VITACCA J CLIN MED. 2019 JUL 18;8(7)

116. CLINICAL METABOLOMICS OF EXHALED BREATH CONDENSATE IN CHRONIC RESPIRATORY DISEASES MANISCALCO M, FUSCHILLO S, PARIS D, SANDUZZI A, MOTTA A. ADVANCES IN CLINICAL CHEMISTRY. 2019 88:121-149
117. EXHALED AND NASAL NITRIC OXIDE MEASUREMENT IN THE DIAGNOSIS OF CHRONIC COUGH. M. MANISCALCO. S. FUSCHILLO, C. GAUDIOSI, A DE FELICE, M MARTUCCI, A MOTTA. NITRIC OXIDE 2019 83:19-23
118. METABOLOMICS APPROACH APPLIED TO BREATH EXHALED CONDENSATE. A METHODOLOGICAL APPROACH. MANISCALCO M, PARIS D, MELCK D, FUSCHILLO S, MOTTA A. CURRENT MEDICAL CHEMISTRY 2019
119. BIOMARKERS IN CLINICAL MANAGEMENT OF PULMONARY HYPERTENSION: HAS THE EMPEROR NO CLOTHES? A CALL FOR ACTION. IANNUZZI GL, D'ALTO M, FORMISANO R, MANISCALCO M. BIOMARK MED. 2019 MAR;13(4):235-238
120. COMPARISON OF THREE DIFFERENT EXHALED NITRIC OXIDE ANALYZERS IN CHRONIC RESPIRATORY DISORDERS. MOLINO A, FUSCHILLO S, MOSELLA M, ACCARDO M, GUIDA P, MOTTA A, MANISCALCO M. J BREATH RES. 2019 6;13(2):021002.
121. THE ANTI-PROLIFERATIVE EFFECTS OF ADIPONECTIN ON HUMAN LUNG ADENOCARCINOMA A549 CELLS AND OXIDATIVE STRESS INVOLVEMENT. NIGRO E, STIUSO P, MATERA MG, MONACO ML, CARAGLIA M, MANISCALCO M, PERROTTA F, MAZZARELLA G, DANIELE A, BIANCO A. PULM PHARMACOL THER. 2019; 55:25-30.
122. DIFFERENTIAL DIAGNOSIS BETWEEN NEWLY DIAGNOSED ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING EXHALED BREATH CONDENSATE METABOLOMICS: A PILOT STUDY. MANISCALCO M, PARIS D, MELCK D, MOLINO A, CARONE M, RUGGERI P., CARAMORI G., MOTTA A. EUROPEAN RESPIRATORY JOURNAL. 2018
123. DESCRIPTION OF A NEW RARE ALPHA-1 ANTITRYPSINE MUTATION IN NAPLES (ITALY): PI*M S-NAPOLI. MOSELLA M, ACCARDO M, MOLINO A, MANISCALCO M, SANDUZZI ZAMPARELLI A. ANNALS OF THORACIC MEDICINE 2018
124. LEFT VENTRICULAR HYPERTROPHY AS PROTECTIVE FACTOR AFTER BYPASS GRAFTING IANNUZZI G, MANISCALCO M, ELIA A, SCOGNAMIGLIO A, FURGI G, RENGO F. MEDICAL HYPOTHESIS. 2018
125. ALLERGIC SENSITIZATION TO COMMON PETS (CATS/DOGS) ACCORDING TO DIFFERENT POSSIBLE MODALITIES OF EXPOSURE. AN ITALIAN MULTICENTER STUDY. LICCARDI G, CALZETTA L, BALDI G, BERRA A, BILLERI L, CAMINATI M, CAPANO P, CARPENTIERI E, MANISCALCO M, ET AL. CLINICAL MOLECULAR ALLERGY 2018
126. CLINICAL AND INFLAMMATORY PHENOTYPING: CAN ELECTRONIC NOSE AND NMR-BASED METABOLOMICS WORK AT THE BEDSIDE? MANISCALCO M, MOTTA A. ARCH MED RES. 2018
127. LONG-TERM EFFECTS OF VASODILATORS IN COMBINED PULMONARY FIBROSIS AND EMPHYSEMA WITH SEVERE PULMONARY HYPERTENSION: A CASE REPORT. FUSCHILLO S, DE FELICE A, DI GRAZIA R, MANISCALCO M. CURRENT RESPIRATORY MEDICINE REVIEWS. 2018
128. PATIENT CONSIDERATIONS IN THE TREATMENT OF COPD: FOCUS ON THE NEW COMBINATION INHALER FLUTICASONE MOLINO A, CALABRESE G, MANISCALCO M. FUROATE / UMECLIDINIUM / VILANTEROL. PATIENT PREFERENCE AND ADHERENCE. 2018
129. ALLERGY IN ADOLESCENT POPULATION (14-18 YEARS) LIVING IN CAMPANIA REGION (SOUTHERN ITALY). A MULTICENTER STUDY." LICCARDI G, CALZETTA L, BALDI G, BERRA A, BILLERI L, CAMINATI M, CAPANO P, CARPENTIERI E, MANISCALCO M, ET AL. EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY. 2018
130. METABOLOMICS OF BREATH IN RESPIRATORY MEDICINE. PARIS D, MANISCALCO M, MOTTA A. EUROPEAN RESPIRATORY JOURNAL. 2018
131. INDOOR ENVIRONMENTAL INTERVENTIONS FOR FURRY PET ALLERGENS: HOW TO DECREASE THE DEGREE OF PASSIVE TRANSPORT? LICCARDI G, CALZETTA L, JACI IN PRACTICE. MANISCALCO M ET AL, 2018
132. IS THERE A ROLE FOR BIOMARKERS IN PULMONARY REHABILITATION? MANISCALCO M, PARIS D, CARONE M, BIOMARKERS IN MEDICINE 2018

133. METABOLOMICS ANALYSIS OF EXHALED BREATH CONDENSATE FROM SUBJECTS AFTER OCCUPATIONAL EXPOSURE USING NUCLEAR MAGNETIC RESONANCE. MANISCALCO M, PARIS D, MELCK D, CHIARIELLO N, DI NAPOLI F, MANNO M, IAVICOLI I, MOTTA A. TOXICOLOGY LETTER 2018 DEC 1; 298:4-12.
134. EFFECT OF PULMONARY REHABILITATION ON FUNCTIONAL EXERCISE CAPACITY AND HYPOXEMIA IN PATIENTS WITH INTERSTITIAL LUNG DISEASES: A RETROSPECTIVE STUDY. FUSCHILLO, S, DE FELICE A, GAUDIOSI C, MARTUCCI M, ELIA A, VITALE D, MANISCALCO M. SARCOIDOSIS AND VASCULAR DISEASE 2018
135. BIOMARKERS IN ALLERGIC ASTHMA: WHICH MATRIX SHOULD WE USE? MANISCALCO M, MOTTA A. CLIN EXP ALLERGY. 2017 AUG;47(8):1097-1098
136. METABOLOMICS OF EXHALED BREATH CONDENSATE: A MEANS FOR PHENOTYPING RESPIRATORY DISEASES? MANISCALCO M, MOTTA A. BIOMARK MED. 2017 MAY;11(6):405-407
137. LONG-TERM EFFECT OF WEIGHT LOSS INDUCED BY BARIATRIC SURGERY ON ASTHMA CONTROL AND HEALTH RELATED QUALITY OF LIFE IN ASTHMATIC PATIENTS WITH SEVERE OBESITY: A PILOT STUDY. MANISCALCO M, ZAMPARELLI AS, VITALE DF, FARAONE S, MOLINO A, ZEDDA A, MOTTA A. RESPIR MED. 2017; 130:69-74.
138. CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN FARMERS: A SYSTEMATIC REVIEW. FONTANA L, LEE SJ, CAPITANELLI I, RE A, MANISCALCO M, MAURIELLO MC, IAVICOLI I. J OCCUP ENVIRON MED. 2017;59(8):775-788
139. NASAL NITRIC OXIDE AS BIOMARKER IN THE EVALUATION AND MANAGEMENT OF CHRONIC RHINO-SINUSITIS WITH NASAL POLYPOSIS. MANISCALCO M. EUR ARCH OTORHINOLARYNGOL. 2017;274(10):3817-3818
140. COEXISTENCE OF OBESITY AND ASTHMA DETERMINES A DISTINCT RESPIRATORY METABOLIC PHENOTYPE. MANISCALCO M, PARIS D, MELCK DJ, D'AMATO M, ZEDDA A, SOFIA M, STELLATO C, MOTTA A. J ALLERGY CLIN IMMUNOL. 2016. PII: S0091-6749(16)31122-8.
141. RECENT ADVANCES ON NITRIC OXIDE IN THE UPPER AIRWAYS. MANISCALCO M, BIANCO A, MAZZARELLA G, MOTTA A. CURR MED CHEM. 2016;23(24):2736-2745.
142. FRACTIONAL EXHALED NITRIC OXIDE MEASURING DEVICES: TECHNOLOGY UPDATE. MANISCALCO M, VITALE C, VATRELLA A, MOLINO A, BIANCO A, MAZZARELLA G. MED DEVICES (AUCKL). 2016 23;9:151-60.
143. METABOLOMICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND OBSTRUCTIVE SLEEP APNEA SYNDROME: A COMMENT. MANISCALCO M, MOTTA A. METABOLOMICS 2016 12(2), 1-2
144. METABOLITES IN EXHALED BREATH CONDENSATE CHARACTERIZE THE OBESE RESPIRATORY PHENOTYPE. D PARIS, M. MANISCALCO, D. MELCK, ET AL. METABOLOMICS 2015 11(4), 1934-39
145. NON-RESPIRATORY SYMPTOMS IN ASTHMA AS POSSIBLE PREDICTORS OF EXACERBATIONS. LICCARDI G, BALDI G, BERRA A, MANISCALCO M, ET AL. J ALLERGY CLIN IMMUNOL PRACT. 2015 3(5) 798-800
146. SMOKING HABIT IN SEVERE OBESE AFTER BARIATRIC PROCEDURES. MANISCALCO M, CARRATÙ P, FARAONE S, CERBONE MR, CRISTIANO S, ZEDDA A, RESTA O. TOB INDUC DIS. 2015 29;13(1):20
147. EXTENDED ANALYSIS OF EXHALED AND NASAL NITRIC OXIDE FOR THE EVALUATION OF CHRONIC COUGH. MANISCALCO M, FARAONE S, SOFIA M, MOLINO A, VATRELLA A, ZEDDA A. RESPIR MED. 2015. 109 (8) 970-4
148. ECHOCARDIOGRAPHIC FINDINGS AND PLASMA ENDOTHELIN-1 LEVELS IN OBESE PATIENTS WITH AND WITHOUT OBSTRUCTIVE SLEEP APNEA. CARRATÙ P, VENTURA VA, MANISCALCO M, DRAGONIERI S, BERARDI S, RIA R, QUARANTA V, VACCA A, DEVITO F, CICCONE M, PHILLIPS B, RESTA O. SLEEP BREATH. 2015 SEP 18
149. LOW ALVEOLAR AND BRONCHIAL NITRIC OXIDE IN SEVERE UNCOMPLICATED OBESITY. MANISCALCO M, ZEDDA A, FARAONE S ET AL. OBES RES CLIN PRACT 2015 9(5) 603-8
150. EXHALED NITRIC OXIDE AND DISEASE PROGRESSION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. MANISCALCO M. J THORAC DIS 2015. 7(3) E59 (LETTER)

151. NMR METABOLOMIC ANALYSIS OF EXHALED BREATH CONDENSATE OF ASTHMATIC PATIENTS AT TWO DIFFERENT TEMPERATURES. MOTTA A, PARIS D, D'AMATO M, MELCK D, CALABRESE C, VITALE C, STANZIOLA AA, CORSO G, SOFIA M, MANISCALCO M. *J PROTEOME RES.* 2014 13(12) 6107-20
152. CLINICAL APPLICATION OF NASAL NITRIC OXIDE MEASUREMENT IN PEDIATRIC AIRWAY DISEASES. MANNA A, MONTELLA S, MANISCALCO M, MAGLIONE M, SANTAMARIA F. *PEDIATR PULMONOL.* 2014. DOI 10.1002/PPUL.23094
153. NOCTURNAL CONTINUOUS POSITIVE AIRWAY PRESSURE IN SEVERE NON-APNEIC ASTHMA. A PILOT STUDY. D'AMATO M, STANZIOLA AA, DE LAURENTIIS G, DIANA R, RUSSO C, MANISCALCO M, D'AMATO G, SOFIA M. *CLIN RESPIR J.* 2014 8(4): 417-424
154. EXHALED NASAL NITRIC OXIDE DURING HUMMING: POTENTIAL CLINICAL TOOL IN SINONASAL DISEASE? MANISCALCO M, PELAIÀ G, SOFIA M. *BIOMARK MED.* 2013 7(2): 261-6
155. SEPARATING SMOKING-RELATED DISEASES USING NMR-BASED METABOLOMICS OF EXHALED BREATH CONDENSATE. DE LAURENTIIS G, PARIS D, MELCK D, MONTUSCHI P, MANISCALCO M, BIANCO A, SOFIA M, MOTTA A. *J PROTEOME RES.* 2013 12(3): 1502-11
156. UPDATE FOR ARTICLES PUBLISHED IN EJCI IN 2011 *EUROPEAN JOURNAL OF CLINICAL INVESTIGATION* 2013 43(10): 1097-1110
157. EXHALED NITRIC OXIDE: CLINICAL APPLICATIONS IN RESPIRATORY DISEASES. SOFIA M, VITALE C, STANZIOLA A, MANISCALCO M. *RASSEGNA ITALIANA IN PATOLOGIA DELL'APPARATO RESPIRATORIO* 2013 28(6): 314-22
158. NUCLEAR MAGNETIC RESONANCE-BASED METABOLOMICS OF EXHALED BREATH CONDENSATE: METHODOLOGICAL ASPECTS. MOTTA A, PARIS D, MELCK D, DE LAURENTIIS G, MANISCALCO M, SOFIA M, MONTUSCHI P. *EUR RESPIR J* 2012 39(2): 498-500
159. RIGHT HEART AND PULMONARY THROMBOEMBOLISM FROM EXTENSIVE SPLANCHNIC VEIN THROMBOSIS AFTER SPLENECTOMY FOR MYELOPROLIFERATIVE DISEASE. STANZIOLA AA, PADULA S, CARPENTIERI E, REA G, MANISCALCO M, SOFIA M. *HEART LUNG.* 2012 41 (2): 188-91.
160. EXPLORING AIRWAY DISEASES BY NMR-BASED METABONOMICS: A REVIEW OF APPLICATION TO EXHALED BREATH CONDENSATE. SOFIA M, MANISCALCO M, DE LAURENTIIS G, PARIS D, MELCK D, MOTTA A. *J BIOMED BIOTECHNOL.* 2011; DOI 2011:403260.
161. MEASUREMENT OF NASAL NITRIC OXIDE BY HAND-HELD AND STATIONARY DEVICES. MONTELLA S, ALVING K, MANISCALCO M, SOFIA M, DE STEFANO S, RAIA V, SANTAMARIA F. *EUR J CLIN INVEST.* 2011 41(10):1063-70
162. OBESITY DURATION IS ASSOCIATED TO PULMONARY FUNCTION IMPAIRMENT IN OBESE SUBJECTS. SANTAMARIA F, MONTELLA S, GRECO L, VALERIO G, FRANZESE A, MANISCALCO M. *OBESITY (SILVER SPRING).* 2011 19(8): 1623-28
163. HAND-HELD NITRIC OXIDE SENSOR NIOX MINO® FOR THE MONITORING OF RESPIRATORY DISORDERS. MANISCALCO M, LUNDBERG JO. *EXPERT REV RESPIR MED.* 2010 4(6): 715-21.
164. ENDOTHELIN-1 IN ACUTE PULMONARY EMBOLISM. SOFIA M, MANISCALCO M. *THROMB RES.* 2010 126(1): E63 (LETTER)
165. EXHALED NITRIC OXIDE AND OTHER MAJOR EXHALED COMPOUNDS FOR THE DIAGNOSIS OF METABOLIC DISEASES. MANISCALCO M, PALLADINO F, SOFIA M. *EXPERT OPINION ON MEDICAL DIAGNOSTICS* 2009 3(5): 547-56
166. EARLY TREATMENT WITH NONINVASIVE POSITIVE PRESSURE VENTILATION PROLONGS SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS WITH NOCTURNAL RESPIRATORY INSUFFICIENCY. CARRATÙ P, SPICUZZA L, CASSANO A, MANISCALCO M. *ORPHANET J RARE DIS.* 2009 4 (1): 10.
167. EXHALED AND ARTERIAL LEVELS OF ENDOTHELIN-1 ARE INCREASED AND CORRELATE WITH PULMONARY SYSTOLIC PRESSURE IN COPD WITH PULMONARY HYPERTENSION. CARRATÙ P, SCODITTI C, MANISCALCO M, *BMC PULM MED.* 2008 26; 8: 20.
168. METABONOMIC ANALYSIS OF EXHALED BREATH CONDENSATE IN ADULTS BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. DE LAURENTIIS G, PARIS D,

MELCK D, MANISCALCO M, *EUR RESPIR J*. 2008 32(5): 1175-83.

169. EXHALED NITRIC OXIDE MONITORING IN COPD USING A PORTABLE ANALYZER. DE LAURENTIIS G, MANISCALCO M, CIANCIULLI F. *PULM PHARMACOL THER*. 2008 21(4): 689-93.
170. CORRELATION OF TRANSABDOMINAL SONOGRAPHIC AND CYSTOSCOPIC FINDINGS IN THE DIAGNOSIS OF FOCAL ABNORMALITIES OF THE URINARY BLADDER WALL: A PROSPECTIVE STUDY. FRANCICA G, BELLINI SA, SCARANO F, MIRAGLIUOLO A, DE MARINO FA, MANISCALCO M. *J ULTRASOUND MED*. 2008 27(6):887-94.
171. EVALUATION OF A TRANSCUTANEOUS CARBON DIOXIDE MONITOR IN SEVERE OBESITY. MANISCALCO M, ZEDDA A, FARAONE S, CARRATÙ P, SOFIA M. *INTENSIVE CARE MED*. 2008 34(7):1340-4.
172. VALIDATION STUDY OF NASAL NITRIC OXIDE MEASUREMENTS USING A HAND-HELD ELECTROCHEMICAL ANALYSER. MANISCALCO M, DE LAURENTIIS G, WEITZBERG E, LUNDBERG JO, SOFIA M. *EUR J CLIN INVEST*. 2008 38(3):197-200.
173. NASAL NITRIC OXIDE ASSESSMENT IN PRIMARY CILIARY DYSKINESIA USING ASPIRATION, EXHALATION, AND HUMMING. SANTAMARIA F, DE STEFANO S, MONTELLA S, BARBARANO F, IACOTUCCI P, CICCARELLI R, SOFIA M, MANISCALCO M. *MED SCI MONIT*. 2008 14(2): 80-85.
174. WEIGHT LOSS AND ASTHMA CONTROL IN SEVERELY OBESE ASTHMATIC FEMALES. MANISCALCO M, ZEDDA A, FARAONE S, CERBONE MR, CRISTIANO S, GIARDIELLO C, SOFIA M. *RESPIR MED*. 2008 102(1):102-8.
175. LONG TERM EFFECT OF BARIATRIC SURGERY ON RESPIRATORY FUNCTION IN SEVERE UNCOMPLICATED OBESITY. MANISCALCO M, ZEDDA A, FARAONE S, GIARDIELLO C, SOFIA M. *THERAPY* 2007 4(5): 555-9
176. CD8+ T-CELL ALVEOLITIS IN FAMILIAL PULMONARY ALVEOLAR MICROLITHIASIS. DE LAURENTIIS G, VITIELLO L, RACIOPPI L, PERNA F, GALGANI M, MEROLA G, CARRATÙ P, MANISCALCO M, MARSICO S, SOFIA M. *EUR RESPIR J*. 2007 30(1): 165-71.
177. NITRIC OXIDE IN UPPER AIRWAYS INFLAMMATORY DISEASES. MANISCALCO M, SOFIA M, PELAIA G. *INFLAMM RES*. 2007 56(2): 58-69.
178. RIGHT VENTRICULAR PERFORMANCE IN SEVERE OBESITY. EFFECT OF WEIGHT LOSS. MANISCALCO M, ARCIELLO A, ZEDDA A, FARAONE S, VERDE R, GIARDIELLO C, CACCIAPUOTI F, CACCIAPUOTI F, SOFIA M. *EUR J CLIN INVEST*. 2007 37(4): 270-5.
179. EXHALED NITRIC OXIDE IN SEVERE OBESITY: EFFECT OF WEIGHT LOSS. MANISCALCO M, DE LAURENTIIS G, ZEDDA A, FARAONE S, GIARDIELLO C, CRISTIANO S, SOFIA M. *RESPIR PHYSIOL NEUROBIOL*. 2007 156(3): 370-3.
180. EFFECT OF BARIATRIC SURGERY ON THE SIX-MINUTE WALK TEST IN SEVERE UNCOMPLICATED OBESITY. M. MANISCALCO, A. ZEDDA, C. GIARDIELLO, FARAONE, M. R. CERBONE, CRISTIANO, M. SOFIA *OBES SURG*. 2006 16: 836-41
181. EXHALED BREATH CONDENSATE AS MATRIX FOR TOLUENE DETECTION: A PRELIMINARY STUDY. MANISCALCO M, DE LAURENTIIS G, PENTELLA C, MORMILE M, SANDUZZI A, CARRATU P, SOFIA M. *BIOMARKERS*. 2006 11: 233-40.
182. SOUNDING AIRFLOW ENHANCES AEROSOL DELIVERY INTO THE PARANASAL SINUSES. M. MANISCALCO, M. SOFIA, E WEITZBERG J LUNDBERG *EUR J CLIN INVEST*. 2006 36: 509-13.
183. BRONCHIAL ASTHMA SYMPTOMS PREVALENCE IN SCHOLAR CHILDHOOD IN NAPPE. DE LAURENTIIS G, MANISCALCO M, FARAONE S, ROSSO V, SOFIA M, ZEDDA A *MINERVA PNEUMOLOGICA* 2006 45(4): 229-36
184. INFLUENCE OF SUBCLINICAL HYPOTHYROIDISM AND T4 TREATMENT ON THE PREVALENCE AND SEVERITY OF OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSAS). RESTA O, CARRATU P, CARPAGNANO GE, MANISCALCO M, DI GIOIA G, LACEDONIA D, GIORGINO R, DE PERGOLA G. *J ENDOCRINOL INVEST*. 2005 28: 893-8.
185. ENDOTHELIN-1 INDUCES PROLIFERATION OF HUMAN LUNG FIBROBLASTS AND IL-11 SECRETION THROUGH AN ET(A) RECEPTOR-DEPENDENT ACTIVATION OF MAP KINASES. GALLELLI L, PELAIA G, D'AGOSTINO B, CUDA G, VATRELLA A, FRATTO D, GIOFFRE V, GALDERISI U, DE NARDO M, MASTRUZZO C, SALINARO ET,

186. ASSOCIATION OF ADAMS-OLIVER SYNDROME WITH PULMONARY ARTERIO-
VENOUS MALFORMATION IN THE SAME FAMILY: A FURTHER SUPPORT TO THE
VASCULAR HYPOTHESIS. M. MANISCALCO, A. ZEDDA, S. FARAONE, G. DE
LAURENTIIS. R. VERDE. V. MOLESE, M. SOFIA *AM J MED GENET A*. 2005 136: 269-74.
187. NASAL NITRIC OXIDE IN EXPERIMENTAL RHINOVIRUS INFECTION. M.
MANISCALCO, M. SOFIA *J ALLERGY CLIN IMMUNOL*. 2005 115: 207-8
188. END POINTS FOR PULMONARY ARTERIAL HYPERTENSION: A WAY BACKWARD.
SOFIA M, MANISCALCO M, CARRATU P, RESTA O. *EUR RESPIR J*. 2004 24: 890-1
189. INCREASE IN EXHALED NITRIC OXIDE IN SHOE AND LEATHER WORKERS AT
THE END OF THE WORK-SHIFT. MANISCALCO M, GRIECO L, GALDI A, LUNDBERG
JO, SOFIA M. *OCCUP MED* . 2004 54:404-7
190. HUMMING-INDUCED RELEASE OF NASAL NITRIC OXIDE FOR ASSESSMENT OF
SINUS OBSTRUCTION IN ALLERGIC RHINITIS: PILOT STUDY. MANISCALCO M,
SOFIA M, WEITZBERG E, DE LAURENTIIS G, STANZIOLA A, ROSSILLO V,
LUNDBERG JO. *EUR J CLIN INVEST*. 2004 34: 555-60
191. NITRIC OXIDE IN EXHALED AIR FOR THE MONITORING OF OCCUPATIONAL
RHINITIS. MANISCALCO M, DI MARE M, MORMILE M, CARRATU P, CARRATU L, SOFIA
M, MANNO M. *GIORNALE ITALIANO IN MEDICINA DEL LAVORO ED ERGONOMIA*
2004 26(4): 80-81
192. NASAL NITRIC OXIDE MEASUREMENTS BEFORE AND AFTER REPEATED
HUMMING MANEUVERS. MANISCALCO M, SOFIA M, WEITZBERG E, CARRATU L,
LUNDBERG JO. *EUR J CLIN INVEST*. 2003 33: 1365-2362
193. HUMMING, NITRIC OXIDE, AND PARANASAL SINUS OBSTRUCTION. LUNDBERG
JO, MANISCALCO M, SOFIA M, LUNDBLAD L, WEITZBERG E. *JAMA* 2003; 289:302-3
194. ASSESSMENT OF NASAL AND SINUS NITRIC OXIDE OUTPUT USING SINGLE-
BREATH HUMMING EXHALATIONS. MANISCALCO M, WEITZBERG E, SUNDBERG J,
SOFIA M, LUNDBERG JO. *EUR RESPIR J* 2003; 22: 323-9
195. RECURRENT FOREIGN BODY ASPIRATION IN THE AIRWAYS IN A
LARYNGECTOMIZED PATIENT. MORMILE M, BALZANO B, MANISCALCO M,
IEPPARELLI G, SANDUZZI A, LEONE CA, SOFIA M. *OTOLARYNG HEAD NECK* 2003
129(1): 152-3
196. ORTHODEOXIA WITHOUT PLATYPNOEA FROM INTERATRIAL DEFECT
ASSOCIATED TO PERSISTENT LEFT SUPERIOR VENA CAVA IN THE ABSENCE OF
PULMONARY HYPERTENSION. MANISCALCO M, DIALETTO G, TUFANO G, ROMANO
A, SOFIA M. *RESPIRATION* 2003 70: 207-210
197. TRANSIENT DECREASE OF EXHALED NITRIC OXIDE AFTER ACUTE EXPOSURE
TO PASSIVE SMOKE IN HEALTHY SUBJECTS. MANISCALCO M, DI MAURO V,
FARINARO E, CARRATÙ L, SOFIA M. *ARCH ENVIRON HEALTH* 2002; 57: 437-40
198. INHALED ULTRASONICALLY NEBULIZED DISTILLED WATER DECREASES
EXHALED NITRIC OXIDE IN ASTHMA. MANISCALCO M, VATRELLA A, PELAIAG, ET
AL. *LUNG* 2002;180: 31-26
199. NITRIC OXIDE ATTENUATES PAF INDUCED NASAL AIRWAY PLASMA
EXTRAVASATION IN HEALTHY SUBJECTS. MANISCALCO M., FERRARA G.,
CARRATÙ L, SOFIA M. *EUR J CLIN INVEST* 2002 32: 858-61
200. EXHALED NITRIC OXIDE AND PASSIVE SMOKE. MANISCALCO M, VATRELLA A,
SOFIA M. *AM J RESP CRIT CARE MED* 2002 165: 1188 (LETTER)
201. EXHALED NITRIC OXIDE AFTER ISOTONIC AND HYPOTONIC SOLUTIONS.
MANISCALCO M, SOFIA M. *MINERVA PNEUMOLOGICA* 2002 41 (3): 113-21
202. EXHALED NITRIC OXIDE AS A MARKER OF ADVERSE RESPIRATORY HEALTH
EFFECT IN ENVIRONMENTAL DISEASE. SOFIA M, MANISCALCO, D'ONOFRIO G,
CARRATU P, VATRELLA A, MONALDI. *ARCHIVES OF CHEST DISEASES* 2002
57(39): 182-7
203. INHIBITION OF NASAL NITRIC OXIDE IN PATIENTS WITH ALLERGIC RHINITIS.
MANISCALCO M, DI MAURO V, SOFIA M. *ANNALI ITALIANI DI MEDICINA*

204. EXHALED NITRIC OXIDE AFTER INHALATION OF ISOTONIC AND HYPOTONIC SOLUTIONS IN HEALTHY SUBJECTS. MANISCALCO M, VATRELLA A, CREMONA G, CARRATÙ L, SOFIA M. *CLIN SCI* 2001 101: 645-50
205. EFFECT OF NITRIC OXIDE INHIBITION ON NASAL AIRWAY RESISTANCE AFTER NASAL ALLERGEN CHALLENGE IN ALLERGIC RHINITIS. MANISCALCO M, SOFIA M, CARRATÙ L, HIGENBOTTAM T. *EUR J CLIN INVEST* 2001 31: 462-66
206. ENDOTHELIN DURING ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. SOFIA M, MANISCALCO M. *THORAX* 2001 56: 819
207. ABNORMALITIES OF RENAL ENDOTHELIN DURING ACUTE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. SOFIA M., MANISCALCO M, CELENTANO L, MORMILE M, FARAONE S, ALIFANO M, CARRATÙ L. *PULM PHARMAC THER* 2001 14: 321-27
208. FAMILIAL OUTBREAK OF DISSEMINATED MULTI-DRUG RESISTANT TUBERCULOSIS AND MENINGITIS. SOFIA M., MANISCALCO M, HONORÈ N, MOLINO A, MORMILE M, HEYM B, COLE ST. *INTER J TUBER LUNG DIS* 2001 5: 551-58
209. EFFECTS OF A NO-SYNTHASE INHIBITOR L-NMMA IN THE HEPATOPULMONARY SYNDROME. MANISCALCO M, SOFIA M, HIGENBOTTAM T. *RESPIRATION* 2001 68: 226
210. THE EFFECT OF PLATELET-ACTIVATING FACTOR (PAF) ON NASAL AIRWAY RESISTANCE IN HEALTHY SUBJECTS IS NOT MEDIATED BY NITRIC OXIDE. MANISCALCO M, SOFIA M, FARAONE S, CARRATÙ L. *ALLERGY* 2000; 55: 757-61
211. NASAL NITRIC OXIDE INHIBITION PREVENTS THE BRADYKININ INDUCED INCREASE IN NASAL AIRWAY RESISTANCE IN NORMAL HUMANS. MANISCALCO M, SOFIA M, GENTILE M, FARAONE S, ALIFANO M, CARRATÙ P. *MINERVA PNEUMOLOGICA* 1997 36 (4): 107-112
212. LACK OF EFFECT OF NITRIC OXIDE INHIBITION ON BRONCHIAL TONE AND METHACHOLINE-INDUCED BRONCHOCONSTRICTION IN MAN. MANISCALCO M, SOFIA M, DEMONCHEAUX EAG, SMITH A, MORMILE M, FARAONE S, HIGENBOTTAM T. *RESP MED* 1997 91: 335-40
213. ENDOTHELIN ABNORMALITIES IN PATIENTS WITH PULMONARY EMBOLISM. SOFIA M, FARAONE S, ALIFANO M, MICCO A, ALBISINNI R, MANISCALCO M, DI MINNO G. *CHEST* 1997; 111: 544-49

CHAPTERS

214. NASAL NITRIC OXIDE. MANISCALCO M, LUNDBERG JO. EUR RESPIRATORY MONOGRAPH 2010 VOL. 49; P. 71-81, ISSN: 1025-448X, DOI: 10.1183/1025448X.00018309
215. EXHALED NO: IDEAS ON ITS ORIGIN AND PHYSIOLOGICAL MEANING. DEMONCHEAUX E.A.G., MANISCALCO M., ROE S., CREMONA G., HIGENBOTTAM T. IN: *NITRIC OXIDE AND OXYGEN RADICALS IN THE PULMONARY VASCULATURE*. WEIR EK ARCHER SL REEVES JT EDS. NY: FUTURA PUBLISHING COMPANY. 1996: 427-45.
216. EXHALED NITRIC OXIDE IN WORKERS EXPOSED TO ORGANIC SOLVENTS. IN: MARONE G. *CLINICAL IMMUNOLOGY AND ALLERGY IN MEDICINE*.

MANISCALCO M., GRIECO L, DE LAURENTIIS G, GALDI A, SOFIA M (2003). P. 607-611, NAPOLI: ED G MARONE. JFC EDITIONS

217. PREVENZIONE DELLE NEOPLASIE POLMONARI E VALUTAZIONE DEL RISCHIO LAVORATIVO. GRIECO L, GRIECO G, MANISCALCO M. *IN*: ONCOLOGIA POLMONARE: GESTIONE DEL PAZIENTE. VIGORITO F ED. 2002; 83-92.
218. OSSIDO NITRICO E FISIOLOGIA DELLE VIE AEREE. SOFIA M, MANISCALCO M, CARRATÙ P, MOLINO A. *IN*: CARDIOLOGIA E PNEUMOLOGIA. FEDELE EDIT. 2001; 16-22.
219. PRODUZIONE DI OSSIDO NITRICO NELL'IPERTENSIONE POLMONARE: IMPLICAZIONI PATOGENETICHE E TERAPEUTICHE. MORMILE M, SOFIA M, FARAONE S, CALVANESE R, MANISCALCO M, CARRATÙ L. *IN*: CARDIOLOGIA E PNEUMOLOGIA. FEDELE EDIT. 1999; 43.
220. ROLE OF ENDOTHELIN IN ACUTE AND CHRONIC PULMONARY DISEASE. SOFIA M., MORMILE M., FARAONE S., MANISCALCO M., ALIFANO M., MICCO A., CARRATÙ P., CARRATÙ L. *IN*: INTERNAL MEDICINE AND ENDOCRINOLOGY PATHOPHYSIOLOGICAL AND CLINICAL INTERACTIONS FABBRINI A AND SANTIEMMA V EDS. 1997; 11-23.
221. FISIOPATOLOGIA DEL CIRCOLO POLMONARE. DE FALCO F., DE LUCIA S., CRISTIANO G., MANISCALCO M., PEZZA A. *IN*: ARGOMENTI DI FISIOPATOLOGIA RESPIRATORIA. PEZZA A ED. NAPOLI: ARIELLO EDITORE 1996; 121-42.
222. OSSIGENO-TERAPIA DOMICILIARE. CRISTIANO G., MANISCALCO M., SCARANO F., DE FALCO F., MARRAZZO R., LIGUORI C., PEZZA A. *IN*: ARGOMENTI DI FISIOPATOLOGIA RESPIRATORIA. PEZZA A ED. NAPOLI: ARIELLO EDITORE 1996; 207-21

Si autorizza al trattamento dei dati ai sensi dell'art. 13 del d. Lgs 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e art. 13 del GDPR (Regolamento UE 2016/679),

15/04/2025



Dr. MAURO MANISCALCO
MNSMRA67R15F839Z
Isc. Albo NA 25712